Who Paid My Doc
A Phase 2, Randomized, Open-Label, Platform Study Utilizing A Master P
Research payments
$1,640,681
Through program year 2025, $1,640,681 in research payments was reported against A Phase 2, Randomized, Open-Label, Platform Study Utilizing A Master P, across 263 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $109,038 | 47 |
| 2024 | Research | $1,156,549 | 138 |
| 2023 | Research | $375,094 | 78 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Harshad Amin Plantation, FL Named on 89 payments
- Mohammed Almubarak Morgantown, WV Named on 20 payments
- Martha Mapalo Albuquerque, NM Named on 20 payments
- Paul Gilman Wynnewood, PA Named on 15 payments
- Atul Kumar Rapid City, SD Named on 11 payments
- Rajan Agarwal Abington, PA Named on 11 payments
- Joseph Yacovone Sleepy Hollow, NY Named on 11 payments
- Wendy Sherman Jacksonville, FL Named on 11 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.